Selpercatinib 40 & 80 mg Tablets in India: For RET Fusion-Positive Cancers
Selpercatinib 40 & 80 mg tablets provide targeted treatment for RET fusion-positive cancers, effectively blocking RET mutations in cancers like non-small cell lung and thyroid cancer. Selpercatinib 40 & 80 mg in India, offers a specialized approach f
Download Presentation
Please find below an Image/Link to download the presentation.
The content on the website is provided AS IS for your information and personal use only. It may not be sold, licensed, or shared on other websites without obtaining consent from the author. Download presentation by click this link. If you encounter any issues during the download, it is possible that the publisher has removed the file from their server.
E N D
Presentation Transcript
(+91) 8750275027 contact@impomedhealthcare.com C-70, SECOND FLOOR OFFICE -A, DDA SHEDS, OKHLA INDUSTRIAL AREA, PHASE- 1, NEW DELHI-110020. Home Who We Are What We Do Diseases Treatment FAQs Contact Us SELPERCATINIB Home | Cancer | Solid Tumors | SELPERCATINIB SELPERCATINIB Capsules Description Composition Dosage Indications Contact Us SELPERCATINIB 40 & 80 MG TABLETS "RETEVMO (selpercatinib) is a kinase inhibitor. RETEVMO (selpercatinib) is supplied as 40 mg or 80 mg hard gelatin capsules for oral use. Each capsule contains inactive ingredients of microcrystalline cellulose and colloidal silicon dioxide. The 40 mg capsule shell is composed of gelatin, titanium dioxide, ferric oxide black and black ink. The 80 mg capsule shell is composed of gelatin, titanium dioxide, FD&C blue #1 and black ink. The black ink is composed of shellac, potassium hydroxide and ferric oxide black. " C-70, SECOND FLOOR OFFICE -A, DDA SHEDS, OKHLA INDUSTRIAL AREA, PHASE- 1, NEW DELHI-110020. +91-9007090388 +91-8750275027 contact@impomedhealthcare.com rahman@impomedhealthcare.com mohan.singh@impomendhealthcare.com Quick Links Diseases Corporate O?ce Home Who We Are What We Do Treatment FAQs Contact Us Blog Cancer Neurology Endocrinology Miscellaneous C-70, SECOND FLOOR OFFICE -A, DDA SHEDS, OKHLA INDUSTRIAL AREA, PHASE- 1, NEW DELHI-110020. , +91-8750275027 +91-9007090388 Established in New Delhi, India in 2020, ImpoMed Healthcare has grown over the years from a new start up to one of the Most Preferred Company for Facilitation of the USFDA/European FDA Approved. contact@impomedhealthcare.com rahman@impomedhealthcare.com Imported Drugs-Only mohan.singh@impomendhealthcare.com Follow us on: Copyright 2024 ImpoMed
